We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
N4 Pharma Plc | LSE:N4P | London | Ordinary Share | GB00BYW8QM32 | ORD 0.4P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.675 | 0.60 | 0.75 | 0.675 | 0.675 | 0.68 | 292,191 | 08:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Drug & Proprietary Stores | 0 | -1.03M | -0.0057 | -1.18 | 1.21M |
Date | Subject | Author | Discuss |
---|---|---|---|
21/8/2018 13:24 | Yet again Nobbo you show yourself to be ill-informed. "The major use of Nuvec is to deliver DNA vaccines" Nuvec has multiple uses for delivery other than vaccines. Had you any knowledge of N4 you would have known that but you haven`t have you. | hughwilson | |
21/8/2018 10:38 | PS oh and as I have said before, Nuvec does have potential....but is not as advanced as you think. What I object to is the vastly over optimistic hype no doubt fed by beloved Nigel on subjects you don't understand. | nobbygnome | |
21/8/2018 10:36 | LOL you are getting desperate hugh.....and again showing your lack of scientific knowledge. The major use of Nuvec is to deliver DNA vaccines. The clue is in the word vaccine. Getting protein expression is not sufficient; you need to show that protein expression leads to an appropriate immune response. That is what is missing.... Please try harder😜! Oh and transcription and translation are crucial to the whole process.....but I guess that is also beyond your scientific understanding. I usually find it is a good idea to comment only on subjects you understand..... Nobby | nobbygnome | |
21/8/2018 10:26 | As a PS, Nobby continues to expose by his responses just how little he knows about N4. I suggest he gets up to speed before making himself look ill-informed. | hughwilson | |
21/8/2018 10:18 | One thing that people cannot deny is that Nuvec has passed every test so far with flying colors in what Nigel describes as fantastic results. Tests are ongoing but N4 talk of a deal for commercial production of its nanoparticles by the end of this year. It also talks of adding further Nuvec deals by the end of this year. All would suggest confidence in the product and its commercialization. With regard transcription of DNA and translation of RNA, Nobbo brought that up to make it sound like he knew what he was talking about but as I said above both of those processes are just pure biology and have no direct bearing on N4 or Nuvec. He says "Give me a link to data showing antibody generation instigated by Nuvec particles.." I quote from an N4 RNS "a single injection of the SiNPs is effective in delivering DNA to generate localized protein expression". He states tolerability is a big issue. I state "No tolerability issues were encountered for the duration of the study", again from an RNS. He now states yeah but no but it has to be replicated, of course it does and that is the work that is going on now. As I said, Nuvec has passed every test with flying colors and confidence is high. Noobo`s response it to write it off so in my opinion regardless of what pharma knowledge Nobbo has or not it is his agenda that is the issue and considering that he is on this board 24/7 deramping the company, its CEO and anyone who is positive then I think that Nobbo`s agenda should be crystal clear to everyone. | hughwilson | |
21/8/2018 09:29 | Jimbo remember Hugh is long a load of 8.5p warrants so he's going to be pumping this for all it's worth until they expire next May..PS I sent you a DM off topic from N4, nothing urgent. | dplewis1 | |
21/8/2018 09:18 | I love the fact we have 2 'experts' on here. I don't trust either of you. One over positive. One overly negative | jimbobaroony | |
21/8/2018 07:28 | From my perspective I don't think any issues can be "put to bed" as such - this tech is so early stage it's impossible to be certain how it will perform in the real world. Until there is either a deal or someone comes out and says it's a non-runner then all you have is a repeating cynics versus believers argument. To quote Rumsfeld, there aren't many "known knowns" with nascent pharma stocks and that is definitely the case with Nuvec. As the guy from SCSW said back in May, N4 is "only for those who want a total speculation". | dplewis1 | |
21/8/2018 06:49 | >> featherby Thank you so much for saying I undoubtedly have Pharma knowledge LOL. It would be surprising if I didn't after working in the industry for 28 years. I have no doubt you have good construction industry knowledge and I wouldn't deign to question it as I haven't a clue. You can be pretty sure that if they had seen good immune response data they would be singing it from the roof tops because that is what it is all about! And in terms of tolerability I worked on something which was in a way similar and the problems seen were not after a few days or weeks but after a few years. Ho hum | nobbygnome | |
21/8/2018 06:22 | Nobby, how can you argue his points? The work is ongoing and only a handful of scientists knows the possibility of the results let alone you. You’ve done your research on Nuvec (as requested) and brought up plenty of negative issues that I’m personally not too convinced is relevant to this specific particle, I’m no expert by the way (construction industry is my background). One thing you have expertly done is raise very few (possibly none) strong points for any of N4’s lineup but claim to have invested. I’m now comfortable to say that you undoubtedly have some Pharma knowledge but lack clarity to make me believe your the real deal, mainly by bringing up issues that’s already been put to bed. We all have a right to speak and voice opinion and I hope we can continue to. | featherby81 | |
21/8/2018 05:31 | LOL good to see you have found out what transcription and translation are by googling! All very good hugh but still no evidence that the injected particles generated the required immune response..... That is all that matters at the end of the day and no-one will sign any deals until that is established. Oh and tolerability needs to be established over many months not just one short study. Naive most definitely is the word...... Keep googling! | nobbygnome | |
20/8/2018 22:51 | Oh, and as for the last weekend, I had it off, away from the de ramping rubbish talked about here. Unlike some, I have other things to do rather than post 24/7 on a chat room. | hughwilson | |
20/8/2018 22:29 | Just out of interest, With regard transcription of DNA and translation of RNA, I don`t see that that has anything to do with N4, but for anyone wanting to find out more then the link below explains this in more detail. | hughwilson | |
20/8/2018 22:11 | Also from the post above- "No tolerability issues were encountered for the duration of the study" Tolerability was one of the issues cited by Nobbo as being an issue when clearly it is not. | hughwilson | |
20/8/2018 21:54 | It is worth noting that the silica nanoparticles to which Nobbo refers are the old silica particles. Nuvec is superior to these in every way with N4 holding the patent for this novel system. To give you an example, the old silica particles delivered as little as 10% to its target whereas the Nuvec particles can deliver up to 90%. The old silica particles showed promise but had their limitations, Nuvec overcomes those limitations which is why Nigel is so excited about the Nuvec platform. | hughwilson | |
20/8/2018 21:39 | Nigel Theobald, CEO of N4 Pharma, commented: "As well as preparing to take our sildenafil reformulation into clinic, we have been scoping out the potential for our nuvec® delivery system and continue to make encouraging progress demonstrating its capability. This signifies another prominent step forward on the road to commercialising nuvec® . We now have evidence that our SiNPs have many desirable features for use in either a vaccine approach or to deliver therapeutic proteins to tissues and are uncovering key commercial advantages compared to lipid nanoparticles. This increases the scope of nuvec's® application which in turn enhances the value of the technology to potential commercial partners. The value of the global nanotechnology drug delivery market is forecast to grow from $4.1 billion in 2014 to $11.9 billion in 2023*. As nuvec® continues to meet its technical targets, it becomes very clear that we have the potential to become a significant player in this growing market. We will continue its development to determine how best to compete and to take the technology forward." | hughwilson | |
20/8/2018 21:38 | "a single injection of the SiNPs is effective in delivering DNA to generate localised protein expression" "In conclusion, a single injection of the SiNPs is effective in delivering DNA to generate localised protein expression at the site of the injection and draining lymph nodes and release cytokines into the systemic circulation. These are all crucial elements for successful cancer therapy treatment. No tolerability issues were encountered for the duration of the study" | hughwilson | |
20/8/2018 21:12 | Give me a link to data showing antibody generation instigated by Nuvec particles..... | nobbygnome | |
20/8/2018 21:10 | The points you raise Nobbo are completely false, as is your reasons for being here. | hughwilson | |
20/8/2018 21:01 | Nobbygnome20 Aug '18 - 19:42 - 765 of 772 "I freely admit I don't know much about the intimate detail of N4P" Congratulations, you actually got something right for a change. | hughwilson | |
20/8/2018 21:01 | LOL the naive one puts in an appearance. It takes one to know one (complete fraud that is!).....Why don't you discuss the points I bring up instead of slagging me off. | nobbygnome | |
20/8/2018 20:58 | Nobbo is a deramper, its as simple as that. Who else buys into a stock and then spends 24/7 slagging the company off, its CEO and anyone who is at all positive. Answer- nobody which is why Nobbo is a complete fraud. | hughwilson | |
20/8/2018 20:15 | SNG and EVG. Simples! | nobbygnome | |
20/8/2018 20:13 | Nobby you called imm correctly who do fancy in drug world ? | tenniselbow |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions